Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Systemic sclerosis
•
Scleroderma
•
Eosinophilic Fasciitis
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
When do you consider adding steroid sparing agents?
Related Questions
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
What Barrett's Esophagus screening protocol do you follow for patients with scleroderma given the increased risk of reflux and esophageal stasis?
What is the clinical significance of an isolated anti-centromere B antibody in a patient with pulmonary fibrosis but no other features of systemic sclerosis?
What considerations do you take when using prednisone in patients with systemic sclerosis?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?